Company: ENBSF
Filing Date: 2025-06-16
Form Type: 424B5
Source: 0001104659-25-059675
Chunk: 57

Company: ENBRIDGE INC
Filing Date: 2025-06-16
Form: 424B5
Chunk 57
---
abilizing transactions consist of certain bids or purchases of Notes made for the purpose of preventing or retarding a decline in the
market price of the Notes while this offering is in progress.

| S-40 |

Any of these activities may
have the effect of preventing or retarding a decline in the market price of the Notes. They may also cause the price of the Notes to be
higher than the price that otherwise would exist in the open market in the absence of these transactions. The underwriters may conduct
these transactions in the over-the-counter market or otherwise. If the underwriters commence any of these transactions, they may discontinue
them at any time. There will be no obligation on Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Mizuho Securities USA LLC
and Wells Fargo Securities, LLC to engage in these activities.

The 2028 Notes, the 2030
Notes and the 2035 Notes are each a new issue of securities and, even though the New 2054 Notes will trade interchangeably with the US$800,000,000
aggregate principal amount of the Existing 2054 Notes, no established trading market exists for any of the Notes. The Notes will not
be listed on any automated dealer quotation system, and we do not intend to apply for listing of the Notes on any securities exchange.
We have been advised that the underwriters currently make a market in the Existing 2054 Notes and that they intend to make a market in
the Notes. However, they are not obligated to do so, and they may discontinue any market-making activities with respect to the Notes
at any time without notice. No assurance can be given as to the liquidity of the trading market for the Notes or that an active public
market for the Notes will develop. If an active public trading market for the Notes does not develop, the market price and liquidity
of the Notes may be adversely affected.

The following table shows
the underwriting discounts and commissions that we will pay the underwriters in connection with this offering (expressed as a percentage
of the principal amount of the Notes).

|                   |     | Paid by  
 Enbridge |   |
| Per 2028 Note     |     |          | % |
| Per 2030 Note     |     |          | % |
| Per 2035 Note     |     |          | % |
| Per New 2054 Note |     |          | % |

We estimate that our total
expenses for this offering, excluding